Program schedule
Time |
Program |
Location |
8:00 – 8:30 am |
Registration, Breakfast, Vendor & Poster Setup |
Foyer |
8:30 – 8:45 am |
Introduction |
Salon E and F |
8:45 – 9:30 am |
Keynote Presentation 1 Drugs and their Delivery: Implications for Billions of Patients and Trillions of Dollars Prof. Samir Mitragotri (Harvard University) |
Salon E and F |
9:30 - 9:45 am |
Vendor Presentation 1 Speeding New Drug Products to Market Patrick Kelleher, FreeThink Technologies |
Salon E and F |
9:45 – 10:00 am |
Break, Vendors, Posters |
Foyer, Salon D |
10:00 am – 12:00 pm |
Academic Research Award (ARA) Presentations Short Topic Presentations (STP) Session 1: Model-Informed Drug Delivery Session 2: Novel Oral Drug Delivery Session 3: Drug Delivery - Other Routes of Administration |
Conference Room 6 Salon A Salon B Salon C |
12:00 – 12:45 pm |
Lunch |
Salon E and F |
12:45 pm - 1:30 pm |
Keynote Presentation 2 Enabling Oral Macromolecule Delivery by Controlling GI Exposure Using Formulation and Modified Softgels Dr. Karanukar Sukuru (Global VP-Pharma, Catalent) |
Salon E and F |
1:30 - 1:45 pm |
Vendor Presentation 2 Leveraging dissoLab and Microstructure Science to Strengthen Regulatory Filings Shawn Zhang, DigiM Solution |
Salon E and F |
1:45 – 3:15 pm |
Round Table Presentations Emerging Technologies - DS and DP Predictive Platforms - DS and DP New Therapeutic Modalities |
Salon A Salon B Salon C |
3:15 – 3:30 pm |
Break, Vendors, Posters |
Foyer and Salon D |
3:30 – 4:30 pm |
Poster Presentations |
Salon D |
4:30 - 4:45 pm |
Awards & Closing Ceremony |
Salon E and F |
4:45 - 5:30 pm |
Networking Reception |
Foyer |
Event Photography
Photographs will be taken throughout the day. Please note that the photographs taken at this event may appear on materials such as our website and LinkedIn page. If you would prefer not to be photographed, please let the photographer know.
MAP
Keynote presentation 1: Drugs and their delivery: implications for billions of patients and trillions of dollars
Abstract:
The quest for new therapies to treat human disease almost always prompts academia and industry to search for new drug molecules. However, a drug molecule must be paired with an appropriate delivery strategy to transform a candidate drug molecule into a successful drug product. Drug delivery is limited by the body’s biological barriers, which manifest in multiple forms, including challenges associated with drug administration and achieving adequate drug concentrations at the target site. These constraints often limit drug efficacy and, ultimately, patient benefit. Our research focuses on understanding the body’s biological barriers and developing strategies to overcome them. I will describe the use of ionic liquids to address key biological barriers and enable the delivery of a broad range of therapeutics. Ionic liquids allow precise control over hydrophobic and ionic interactions within the body, providing a powerful means to modulate biological barriers. I will present the scientific foundation of ionic liquids for therapeutic applications, their ability to overcome multiple biological barriers in clinical outcome, and address unmet clinical needs, and the future opportunities they present.
The quest for new therapies to treat human disease almost always prompts academia and industry to search for new drug molecules. However, a drug molecule must be paired with an appropriate delivery strategy to transform a candidate drug molecule into a successful drug product. Drug delivery is limited by the body’s biological barriers, which manifest in multiple forms, including challenges associated with drug administration and achieving adequate drug concentrations at the target site. These constraints often limit drug efficacy and, ultimately, patient benefit. Our research focuses on understanding the body’s biological barriers and developing strategies to overcome them. I will describe the use of ionic liquids to address key biological barriers and enable the delivery of a broad range of therapeutics. Ionic liquids allow precise control over hydrophobic and ionic interactions within the body, providing a powerful means to modulate biological barriers. I will present the scientific foundation of ionic liquids for therapeutic applications, their ability to overcome multiple biological barriers in clinical outcome, and address unmet clinical needs, and the future opportunities they present.
Prof. Samir Mitragotri, Harvard University
Samir Mitragotri is the Hiller Professor of Bioengineering and Wyss Professor of Biologically Inspired Engineering at Harvard University. His research focuses on drug delivery and has led to the development of new technologies for delivering small molecules, proteins, nucleic acids, and cell therapies, including multiple technologies, including microneedles, ultrasound, lipid nanoparticles, and cellular backpacks, to enable drug delivery across multiple biological barriers and to enable transdermal targeting.
Samir is an elected member of the U.S. National Academy of Engineering, the U.S. National Academy of Medicine, and the U.S. National Academy of Sciences, and the World Academy of Sciences. He is also an elected Fellow of the American Association for the Advancement of Science, Controlled Release Society, Biomedical Engineering Society, and American Association of Pharmaceutical Scientists. His work has led to the founding of over a dozen biotechnology companies that have advanced technologies into the clinic. He received his B.S. in Chemical Engineering from the Indian Institute of Technology, Madras, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Samir is an elected member of the U.S. National Academy of Engineering, the U.S. National Academy of Medicine, and the U.S. National Academy of Sciences, and the World Academy of Sciences. He is also an elected Fellow of the American Association for the Advancement of Science, Controlled Release Society, Biomedical Engineering Society, and American Association of Pharmaceutical Scientists. His work has led to the founding of over a dozen biotechnology companies that have advanced technologies into the clinic. He received his B.S. in Chemical Engineering from the Indian Institute of Technology, Madras, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Vendor Presentation 1: Speeding New Drug Products to Market
Patrick Kelleher, Associate Director of Physical Sciences
FreeThink Technologies
[email protected]
Abstract
Learn about scientifically driven accelerated stability modeling using ASAPprime® and how it can be applied, from pre-formulation through post-approval, to help speed new drug products to market.
Bio
Patrick Kelleher received his B.S. (Stonehill College) and Ph.D. (Yale University) in physical chemistry before completing post-doctoral studies at the University of Virginia. His graduate and post-doctoral work focused on the development of spectroscopic and mass-spectrometric techniques for structural elucidation of small molecules. Patrick joined FreeThink in 2020 where he currently leads the physical sciences department in designing and executing rapid and material-sparing stability studies using FreeThink's ASAPprime? software.
FreeThink Technologies
[email protected]
Abstract
Learn about scientifically driven accelerated stability modeling using ASAPprime® and how it can be applied, from pre-formulation through post-approval, to help speed new drug products to market.
Bio
Patrick Kelleher received his B.S. (Stonehill College) and Ph.D. (Yale University) in physical chemistry before completing post-doctoral studies at the University of Virginia. His graduate and post-doctoral work focused on the development of spectroscopic and mass-spectrometric techniques for structural elucidation of small molecules. Patrick joined FreeThink in 2020 where he currently leads the physical sciences department in designing and executing rapid and material-sparing stability studies using FreeThink's ASAPprime? software.
Academic Research Awards (ARA) Presentations
Conference Room 6
Conference Room 6
Time |
Title |
Presenter |
Affiliation |
10:00 - 10:20 am |
Structural Basis of Drug Binding to Human Cytochrome P450 2C9: Insights into the Impact of Single Nucleotide Polymorphism |
Richa Trivedi |
Albany College of Pharmacy and Health Sciences |
10:25 - 10:45 am |
Scalable Continuous Manufacturing of Multi-drug Liposomes: Tuning Size and PDI via Post-loading |
Luke Burroughs |
University of Connecticut |
10:50 - 11:10 am |
Angiopep anchored PROTAC Nanotherapy for Glioblastoma using Bioorthogonal Click Chemistry |
Himaxi Patel |
St. John's University |
11:15 - 11:35 am |
Nanovesicles in Broccoli Sprouts for Targeted and Enhanced Therapy of Inflammatory Bowel Disease |
Mansi More |
Western New England University |
11:40 am - 12:00 pm |
More Than Digestion: Alternative In Vitro Methods for Evaluating Lipid-Based Formulations |
Sushil Joshi |
University of Connecticut |
Short Topic Presentations (STP) Session 1: Model-Informed Drug Delivery
Salon A
Salon A
Time |
Title |
Presenting Author |
Affiliation |
10:00 - 10:30 am |
Molecular Modeling-Based Prediction of the Stability of Biopharmaceutical API Under Different Buffer Condition |
Gloria Agyapong |
Pharmaceutical Sciences, University of Connecticut, Storrs, CT |
10:30 - 11:00 am |
Investigating the Particle Drifting Effect in the Human Jejunum Using Computational Fluid Dynamics |
M Rasheed Anjum |
Pharmaceutical Sciences, University of Connecticut, Storrs, CT |
11:00 - 11:30 am |
ZoomLab-Enabled Design & Development of Loratadine Tablets - Mechanistic Insights into Binder and Tooling Influence on Dissolution Behavior and IVIVC Outcomes |
Sravani Reddy |
College of Pharmacy and Health Sciences, St. John’s University, Queens, NY |
11:30 am - 12:00 pm |
Computer Vision for API dissolution |
James Min |
Pfizer Inc., Groton, CT |
Short Topic Presentations (STP) Session 2: Novel oral drug delivery
Salon B
Salon B
Time |
Title |
Presenting Author |
Affiliation |
10:00 - 10:30 am |
Formulation development of extemporaneously prepared mucoadhesive in situ forming oral gels for phase 1 clinical studies |
Radha Kulkarni |
School of Pharmacy, University of Connecticut, Storrs, CT |
10:30 - 11:00 am |
Nanoliposomal Formulation of lipophilic Gemcitabine derivative for the Treatment of naïve and drug resistance brain cancer |
Bhoomi Dholariya |
College of Pharmacy and Health Sciences, St. John’s University, Queens, NY |
11:00 - 11:30 am |
A Novel Oral Excipient for Solid Dosage Forms – Formulation Development, Characterization, and IVIVC Prediction |
Zia Uddin Masum |
College of Pharmacy and Health Sciences, St. John’s University, Queens, NY |
11:30 am - 12:00 pm |
Data-Driven Formulation of Solid Oral Dosage Forms: Integrating Computational Modeling with Experimental Validation Using ZoomLab |
Suman Choudhary |
College of Pharmacy and Health Sciences St. John’s University, Queens, NY |
Short Topic Presentations (STP) Session 3: Drug delivery - Other Routes of Administration
Salon C
Salon C
Time |
Title |
Presenting Author |
Affiliation |
10:00 - 10:30 am |
Evaluating In Vitro Release Strategies for Oily Depot Solutions |
Saurabh Badole |
University of Connecticut, School of Pharmacy, Storrs, CT |
10:30 - 11:00 am |
Kidney-Targeted siRNA Delivery Using Mesoscale Lipid Nanoparticles |
Anastasiia Vasylaki |
Department of Biomedical Engineering, City College of New York, New York, NY |
11:00 - 11:30 am |
Novel phosphoantigen prodrug platform with integrated HILIC–MS/MS bioanalysis for γδ T-cell based cancer immunotherapy |
Girija Pawge |
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT |
11:30 am - 12:00 pm |
Pulmonary Delivery of Spray-Dried Antimalarial Drug: A novel Inhaled Formulation for Non-Small Cell Ling Cancer Treatment |
Meghana Mokashi |
College of Pharmacy and Health Sciences, St. John’s University, Queens, NY |
Keynote presentation 2: Enabling oral macromolecule delivery by controlling GI Exposure using formulation and modified softgels
Abstract:
Oral delivery of macromolecules is limited by gastric acidity, enzymatic degradation, and low intestinal permeability. Under these constraints, formulation-controlled gastrointestinal exposure often determines whether absorption is possible in vivo. Advances in delayed-release softgel technologies, combined with lipid-based formulations, enable protection from gastric processing and targeted intestinal release. When aligned with permeability enhancement, these systems better support absorption. This presentation examines how controlling release location can improve the likelihood of oral absorption for proteins and peptides. Key biopharmaceutical barriers and dissolution-relevant learnings from modified softgel platforms and biorelevant testing approaches will be discussed using recent internal case examples.
Oral delivery of macromolecules is limited by gastric acidity, enzymatic degradation, and low intestinal permeability. Under these constraints, formulation-controlled gastrointestinal exposure often determines whether absorption is possible in vivo. Advances in delayed-release softgel technologies, combined with lipid-based formulations, enable protection from gastric processing and targeted intestinal release. When aligned with permeability enhancement, these systems better support absorption. This presentation examines how controlling release location can improve the likelihood of oral absorption for proteins and peptides. Key biopharmaceutical barriers and dissolution-relevant learnings from modified softgel platforms and biorelevant testing approaches will be discussed using recent internal case examples.
Karunakar Sukuru, R.Ph., Ph.D., Global Vice President, Catalent
Karunakar Sukuru is a distinguished leader in the pharmaceutical industry, with over three decades of expertise in Drug Product and Technology Development. At Catalent, he oversees the development of small molecule Rx products, guiding a team of over 800 scientists across 14 sites on four continents. His role involves managing a robust pipeline of several new molecules, utilizing diverse drug delivery technologies to support successful product launches.
With over three decades of experience, Karunakar has a proven track record in product development and technical oversight of numerous Contract Development and Manufacturing Organizations (CDMOs) globally. He is renowned for pioneering innovative controlled-release platform technologies in softgel dosage forms. He holds several granted patents and has over 20 pending patent applications, particularly in modified shell, fill technologies and lyophilization techniques for biologic products.
Before joining Catalent in 2016, Karunakar held key positions at Endo Pharmaceuticals, Banner Pharmacaps (in India and USA), and Natco Pharma in India, demonstrating his extensive leadership in the field.
He is actively involved (invited speaker) in professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), Controlled Release Society (CRS), Society for Pharmaceutical Dissolution Science (SPDS), and served as an expert committee member at the United States Pharmacopeia (USP), for 10 years, where he contributed to setting pharmaceutical standards.
With over three decades of experience, Karunakar has a proven track record in product development and technical oversight of numerous Contract Development and Manufacturing Organizations (CDMOs) globally. He is renowned for pioneering innovative controlled-release platform technologies in softgel dosage forms. He holds several granted patents and has over 20 pending patent applications, particularly in modified shell, fill technologies and lyophilization techniques for biologic products.
Before joining Catalent in 2016, Karunakar held key positions at Endo Pharmaceuticals, Banner Pharmacaps (in India and USA), and Natco Pharma in India, demonstrating his extensive leadership in the field.
He is actively involved (invited speaker) in professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), Controlled Release Society (CRS), Society for Pharmaceutical Dissolution Science (SPDS), and served as an expert committee member at the United States Pharmacopeia (USP), for 10 years, where he contributed to setting pharmaceutical standards.
VENDOR PRESENTATION 2: Leveraging dissoLab and microstructure science to strengthen regulatory filings
Shawn Zhang, Founder, CEO
digiM Solution
[email protected]
Abstract
As FDA increasingly incorporates microstructure-based characterization into its regulatory expectations — most recently exemplified in the 2025 revised Product-Specific Guidance (PSG) for Minocycline Hydrochloride Dental Extended Release Microspheres (PSG_050781), which mandates characterization of microsphere porosity, drug particle size, and spatial drug distribution using at least two orthogonal methods — pharmaceutical developers need scalable tools to NDA, ANDA, and post-approval change submissions.
This presentation introduces dissoLab, a software platform that integrates image-based microstructure analysis with physics-based dissolution simulation to bridge the gap between microstructure characterization and release performance prediction in vitro and in vivo. By digitizing internal drug product microstructures through modalities such as micro-CT and FIB-SEM and simulating dissolution profiles through these digital twins, dissoLab enables sponsors to build mechanistic, audit-ready evidence linking formulations and manufacturing process variables to critical quality attributes (CQAs). This microstructure-to-performance approach supports comparability arguments across manufacturing scales, sites, and process changes — directly addressing SUPAC, ANDA comparability, and complex product bioequivalence requirements.
Case studies across amorphous solid dispersions and long acting injectables will demonstrate how microstructure-informed dissoLab predictions reduces reliance on purely empirical dissolution testing, strengthens CMC narratives, and facilitates more efficient regulatory review.
References
● FDA Draft Guidance, Minocycline Hydrochloride, Powder, Extended Release, Dental, EQ 1 mg Base — PSG_050781 (Recommended Mar 2015; Revised Nov 2025). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050781.pdf
● Dissolution prediction from images: method and validation of dissoLab platform. AAPS Open 11:19 (2025), Available at: https://link.springer.com/article/10.1186/s41120-025-00122-6
Bio
Shawn is founder and CEO of digiM based in Boston. Shawn and his digiM team are passionate about the combined power of experimental measurements and computational physics simulations (thus I2S – digiM’s flagship image to simulation software platform). With over hundreds of publications, patents, and software products, Shawn leads digiM to becoming a trusted partner in the characterization, institutionalization, and democratization of microstructure science across multiple industries. Shawn graduated from Rutgers University with a Ph.D. in Computational Physics and a minor in Computer Engineering. Before starting digiM, Shawn held senior positions at leading CAE software company Fluent (now Ansys) and leading electron microscopy company FEI (now ThermoFisher). Learn more about Shawn’s work in Google Scholar or LinkedIn.
digiM Solution
[email protected]
Abstract
As FDA increasingly incorporates microstructure-based characterization into its regulatory expectations — most recently exemplified in the 2025 revised Product-Specific Guidance (PSG) for Minocycline Hydrochloride Dental Extended Release Microspheres (PSG_050781), which mandates characterization of microsphere porosity, drug particle size, and spatial drug distribution using at least two orthogonal methods — pharmaceutical developers need scalable tools to NDA, ANDA, and post-approval change submissions.
This presentation introduces dissoLab, a software platform that integrates image-based microstructure analysis with physics-based dissolution simulation to bridge the gap between microstructure characterization and release performance prediction in vitro and in vivo. By digitizing internal drug product microstructures through modalities such as micro-CT and FIB-SEM and simulating dissolution profiles through these digital twins, dissoLab enables sponsors to build mechanistic, audit-ready evidence linking formulations and manufacturing process variables to critical quality attributes (CQAs). This microstructure-to-performance approach supports comparability arguments across manufacturing scales, sites, and process changes — directly addressing SUPAC, ANDA comparability, and complex product bioequivalence requirements.
Case studies across amorphous solid dispersions and long acting injectables will demonstrate how microstructure-informed dissoLab predictions reduces reliance on purely empirical dissolution testing, strengthens CMC narratives, and facilitates more efficient regulatory review.
References
● FDA Draft Guidance, Minocycline Hydrochloride, Powder, Extended Release, Dental, EQ 1 mg Base — PSG_050781 (Recommended Mar 2015; Revised Nov 2025). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050781.pdf
● Dissolution prediction from images: method and validation of dissoLab platform. AAPS Open 11:19 (2025), Available at: https://link.springer.com/article/10.1186/s41120-025-00122-6
Bio
Shawn is founder and CEO of digiM based in Boston. Shawn and his digiM team are passionate about the combined power of experimental measurements and computational physics simulations (thus I2S – digiM’s flagship image to simulation software platform). With over hundreds of publications, patents, and software products, Shawn leads digiM to becoming a trusted partner in the characterization, institutionalization, and democratization of microstructure science across multiple industries. Shawn graduated from Rutgers University with a Ph.D. in Computational Physics and a minor in Computer Engineering. Before starting digiM, Shawn held senior positions at leading CAE software company Fluent (now Ansys) and leading electron microscopy company FEI (now ThermoFisher). Learn more about Shawn’s work in Google Scholar or LinkedIn.
Round table session 1: emerging technologies - DS and DP
Salon A
Salon A
Presentation Title |
Invited Presenter |
Affiliation |
Breaking the Barrier: Resolving CMC Challenges with DS–DP Co‑Processing |
Dr. Bing-Shiou Yang |
Boehringer Ingelheim |
Phase understanding to guide process control for patient centric microsphere formulations |
Dr. Heather Frericks Schmidt |
Pfizer Inc. |
Liquid-Liquid Phase Separation in Formulation and Crystallization Development |
Prof. Na Li |
University of Connecticut |
round table session 2: Predictive Platforms - DS and DP
salon b
salon b
Presentation Title |
Invited Presenter |
Affiliation |
Model-based predictive tools to assess critical quality attributes of drug products |
Dr. Shubhajit Paul |
Boehringer Ingelheim |
A Predictive Modeling Platform for Accelerating Drug Substance, Drug Product, Formulation Development and Delivery Timelines |
Dr. Shiva Shekharan |
Schrodinger |
Mechanistically Informed Predictive Platforms for Modified-Release Tablet Products: Enabling Strength Scaling and Risk-Based Development |
Prof. Jie Shen |
Northeastern University |
round table session 3: New Therapeutic Modalities
salon C
salon C
Presentation Title |
Invited Presenter |
Affiliation |
TBD |
Dr. Manjunatha Shivaraju |
Boehringer Ingelheim |
Beyond intrathecal: less-invasive oligonucleotide delivery across BBB |
Prof. Anisha DSouza |
Northeastern University |
Multilayer Nanoplatforms for Effective Therapeutic Delivery to the Lungs |
Prof. Vivek Gupta |
St. John’s University |
Poster Presentations
Salon D
Salon D
Click on Poster # for Poster Abstract
Poster # |
Presenter |
TItle |
Affiliation |
Spencer Leonette |
Developing and Integrating Pharmaceutical Analytical Techniques Lab Platforms for Preformulation, Bioassay and Pharmacokinetic Simulation |
Albany College of Pharmacy and Health Science |
|
Hamayal Sharma |
Programmable Antisense Nucleic Acid Mimics as Targeted Antibiotics |
University of Connecticut |
|
Saurabh Bhorkade |
Impact of polymer residual content on properties and performance of risperidone microspheres |
University of Connecticut |
|
Purvi Neema |
Data Curation for Physics-Informed Cardiotoxicity Prediction via Benchmarking of hERG Pose Generation Workflows |
University of Connecticut |
|
Christine Napiany |
Mask and You Shall Receive: Novel Taste Masked Coating Strategies for Flexible Oral Solids |
Pfizer |
|
Kevin Ramirez Garcia |
Potential of L-Canavanine for Cancer Therapy |
University of Saint Joseph |
|
Bhoomi Dholariya |
Hydrophobic ion pairing facilitated self-Nanoemulsifying Drug Delivery System of Niclosamide for cancer treatment |
St. John’s University |
|
Saeed Najafian |
Continuous Manufacturing of Biological Drug Products for Pulmonary Drug Delivery |
University of Connecticut |
|
Saeed Najafian |
Understanding Particle Attrition for Reactive Systems and Crystallization with CFD-DEM Predictions |
University of Connecticut, AbbVie |
|
Phani Vatsavai |
The Synergistic Inhibitory Effect of Targeting CCL5 and Endoglin in Endocrine-Resistant Mammary Tumors |
Albany College of Pharmacy and Health Sciences |
|
Umang Shah |
Pembrolizumab as an Immune Checkpoint Blockade Therapy in Syngeneic Triple Negative Breast Cancer Models |
Albany College of Pharmacy and Health Sciences |
|
Roshni Chavan |
Structural and Functional Basis of Drug Binding to Human Cytochrome P450 2C8 |
Albany College of Pharmacy and Health Sciences |
|
Mural Quadros |
Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles as a Novel Delivery System for Mesothelioma Treatment |
St John’s University |
|
Sanjana Durve |
Development of Spray-Dried Solid Dispersions of Edaravone for Enhanced Oral Delivery |
St John’s University |
|
Reshma Sarkar |
Vortioxetine-Loaded Liposomes: A Repurposed Approach for Glioblastoma therapies |
St John’s University |
|
Kranthi Gattu |
Design of a Solid Supersaturated Self-Nanoemulsifying System: Role of Apinovex in Modulating Drug Precipitation |
St John’s University |
|
Ajinkya Khedekar |
Spray drying of poorly water-soluble drugs without any organic solvent using the acid-base supersolubilization (ABS) principle |
St John’s University |
|
Priyanka Panchal |
Nano-Orlis Microneedle Delivery System for treatment of Acne Vulgaris |
St. John’s University |
|
Drishti Rathod |
Combinatorial nanomedicine strategy to remodel tumor stroma and degrade BRD4 to treat pancreatic ductal adenocarcinoma |
St. John’s University |
|
Naveen Rajana |
Novel Dual-Ligand-Conjugated Hybrid Nanoparticles for Targeted Delivery of Lorlatinib to Lung Cancer Cells |
St. John’s University |
|
Akanksha Ugale |
A DoE Driven 3D-Printed T-Junction Microfluidic Platform for Fabrication of Targetable Liposomes in Anticancer Drug Delivery |
St. John’s University |
|
Shashank Reddy Pasika |
Comparative Evaluation of Spray Drying And Freeze Drying Using Different Stabilizers For Solidification Of Nanosuspension |
St. John’s University |
|
Varsha Mundrathi |
Inhalable Alectinib PLGA Microparticles for ALK-Positive Non-Small Cell Lung Cancer Treatment |
St. John’s University |
|
Parasharamulu Kommarajula |
Fabricating Inhalable PLGA Nanoparticles for Targeted Therapy in Non-small Cell Lung Cancer |
St. John’s University |
|
Leila Sharifi |
Understanding the Role of Poloxamer 188 in inhibiting AAV8 Capsid Aggregation: A Coarse-Grained Molecular Dynamics Study |
University of Connecticut |
|
Leila Sharifi |
Mechanistic Differences of NaCl vs. MgCl₂ in Preventing AAV8 Capsid Aggregation |
University of Connecticut |
|
Saurav Adhikari |
Impact of impurity and API properties on oiling-out behavior |
University of Connecticut |
|
Pawan Kumar Pandey |
Understanding the impact of porosity on in vitro performance of PLGA microspheres |
University of Connecticut |
|
Jobair Hossen |
Impact of Freezing Parameters and Cryoformulation Design on Post-Thaw Viability of Jurkat Cells |
University of Connecticut |
|
Rutu Valapil |
Impact of antioxidant addition on drug dissolution: Implications for NDSRI mitigation biowaivers |
University of Maryland |
|
Dylan Mattison |
Analysis of Pembrolizumab in Biological Samples Using Sampling by ABS Plastic SPME and Quantitation by LC-MS/MS |
Albany College of Pharmacy and Health Sciences |
|
Pratyusha Ghosh |
Targeted Polymer Mesoscale Nanoparticle Therapies for Glomerular Disease |
City College of New York, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Pennsylvania,Stony Brook University |
|
Atara R. Israel |
Detection of Anthracycline Accumulation Using Optical Spectral Fingerprinting |
City College of New York, Georgia Institute of Technology, Hanyang University, Seoul, Stony Brook University |
|
Shekh Md Newaj |
A First-in-Class Perfluorocarbon-Loaded Solid Lipid Nanoparticles for Oxygen Delivery |
Duquesne University |
|
Smith Patel |
Scalable Perfluorocarbon Nanoemulsions for Oxygen and Resveratrol Delivery to Prevent Ischemia-Reperfusion Injury During Organ Preservation |
Duquesne University |
|
Ruchi Thombre |
Expanding the design space of swellable core technology (SCT) for delivery of higher doses and patient centric dosage form |
Pfizer |
|
Nidhi Gevariya |
Biosurfactant Stabilized Oral Nanosuspension of Vortioxetine hydrobromide for Treatment of Glioblastoma |
St. John’s University |
|
Alice Han and Michael Tang |
Impact of Cryoformulation Contact Time on Jurkat Cell Viability |
University of Connecticut, Northern Valley Regional High School at Old Tappan |
|
Efren Alvidrez |
Making Disintegration Measurable: A Computer Vision-Enabled Disintegration Device for Mechanistic Insight |
Pfizer |
28th Annual AAPS-NERDG Conference Sponsors
Corporate Sponsors/Donors
Merck
GSK
Pfizer
Amgen
Boehringer Ingelheim
Other Sponsors/Exhibitors
Free Think Technologies
DigiM Solution
JRS Pharma
Distek Inc.
Sever Pharma Solutions
Schrödinger
Sotax
Triclinic Labs
Asahi Kasei
Corealis Pharma
Barentz
The Solubility Company
Persist AI
